NLS Pharmaceutics Ltd Stock

$3.56

3.79% yesterday

Nasdaq, Nov 25, 10:00 pm CET

ISIN

CH0523961370

Symbol

NLSP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

NLS Pharmaceutics Ltd Stock price

$3.56

-112.04 96.92% 5Y

Nasdaq, Closing price Mon, Nov 25 2024

+0.13 3.79%

ISIN

CH0523961370

Symbol

NLSP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$8.80m
Enterprise Value	$9.96m
P/E (TTM) P/E ratio	negative
P/B ratio (TTM) P/B ratio	negative
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-6.31m
EPS (TTM) EPS	$-0.19
P/E forward	negative
Short interest	0.66%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

NLS Pharmaceutics Ltd Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast NLS Pharmaceutics Ltd:

1x Hold

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast NLS Pharmaceutics Ltd:

Hold

100%

Analyst Estimates with Stock Price Targets

Financial data from NLS Pharmaceutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.01 0.01	0% 0% -
Gross Profit	-0.01 -0.01	0% 0% -
- Selling and Administrative Expenses	4.49 4.49	31% 31% -
- Research and Development Expense	1.80 1.80	77% 77% -
EBITDA	-6.30 -6.30	56% 56% -
- Depreciation and Amortization	0.01 0.01	0% 0% -
EBIT (Operating Income) EBIT	-6.31 -6.31	56% 56% -
Net Profit	-6.60 -6.60	57% 57% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

NLS Pharmaceutics Ltd Stock News

Neutral

Accesswire

●

8 days ago

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

ZÜRICH, SWITZERLAND / ACCESSWIRE / November 18, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, provided insights today into the preclinical program evaluating its dual orexin re...

Neutral

Accesswire

●

22 days ago

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / November 4, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company, and Kadimastem Ltd.

Neutral

Accesswire

●

29 days ago

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

ZURICH, SWITZERLAND / ACCESSWIRE / October 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has received notice from the Nasdaq Stock Market LLC ("NASD...

More NLS Pharmaceutics Ltd News

Company Profile

NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder(ADHD). The company was founded by Ronald Hafner and Alexander Zwyer in August 2015 and is headquartered in Stans, Switzerland.

Head office	Switzerland
CEO	Alexander Zwyer
Employees	4
Founded	2015
Website	www.nlspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now